MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Juno Therapeutics Company Profile (NASDAQ:JUNO)

Consensus Ratings for Juno Therapeutics (NASDAQ:JUNO) (?)
Ratings Breakdown: 2 Hold Rating(s), 11 Buy Rating(s)
Consensus Rating:Buy (Score: 2.85)
Consensus Price Target: $58.27 (44.31% upside)

Analysts' Ratings History for Juno Therapeutics (NASDAQ:JUNO)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Cowen and CompanyInitiated CoverageOutperform$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016SunTrustReiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016Maxim GroupReiterated RatingBuy$78.00 -> $80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Morgan StanleyBoost Price Target$48.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2016Leerink SwannReiterated RatingOutperform$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2016Deutsche BankInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$50.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/17/2016GuggenheimUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016JPMorgan Chase & Co.Reiterated RatingOverweight$69.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2015Standpoint ResearchUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015Northland SecuritiesInitiated CoverageOutperform$64.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha